At its 16 June 2022 meeting in Amsterdam, the European Medicines Agency’s (EMA) Management Board elected Christelle Ratignier-Carbonneil as vice-Chair of the Board for a three-year period. Christelle Ratignier-Carbonneil replaces Lorraine Nolan, who was elected as Management Board Chair at its March 2022 meeting.
The Chair also welcomed three new civil society representatives – Virginie Hivert, Denis Lacombe, Despoina Iatridou, as well as Karin Kadenbach as new representative from the European Parliament (EP) to the Board. Marco Grecowas congratulated on his re-appointment as representative of patients’ organisations and Anthony Borg as EP representative.
EMA updated the Board about the efforts made by the Agency in monitoring the impact of the war in Ukraine on the supply of medicines in the European Union (EU) and the situation deriving from the international outbreak of Monkeypox.
The Board heard an update on the COVID-19 products authorised since the last meeting in March. EMA reported on the current efforts to adapt the composition of the authorised COVID-19 mRNA vaccines to target Omicron variants in time for the vaccination campaigns this autumn. The first results from clinical trials are expected to become available very soon. Manufacturers are already preparing their applications for adapted vaccines. Initial packages of data have been submitted for rolling review by Biontech/Pfizer and Moderna…